Evidence map›Paper›PMID 27621732›Full record

ArticleFrontiers in immunology2016

Combination of In Silico Methods in the Search for Potential CD4(+) and CD8(+) T Cell Epitopes in the Proteome of Leishmania braziliensis.

Rafael de Freitas E Silva, Luiz Felipe Gomes Rebello Ferreira, Marcelo Zaldini Hernandes, Maria Edileuza Felinto de Brito, Beatriz Coutinho de Oliveira, Ailton Alvaro da Silva, Osvaldo Pompílio de-Melo-Neto, Antônio Mauro Rezende, Valéria Rêgo Alves Pereira

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evaluation of the Antigenic Potential of Epitopes Derived FromBioinformatics and biology insights · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Probing theBiomedicines · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Frontiers in chemistry · 2020
    Article
  15. Article
  16. Article
  17. Immunogenicity of Potential CD4Frontiers in immunology · 2019
    Article
  18. The F1F3 Recombinant Chimera ofFrontiers in immunology · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Rafael de Freitas E SilvaDepartment of Natural Sciences, Universidade de Pernambuco, Garanhuns, Pernambuco, Brazil; Department of Immunology, Fundação Oswaldo Cruz, Recife, Pernambuco, Brazil.
Luiz Felipe Gomes Rebello FerreiraDepartment of Pharmaceutical Sciences, Universidade Federal de Pernambuco , Recife, Pernambuco , Brazil.
Marcelo Zaldini HernandesDepartment of Pharmaceutical Sciences, Universidade Federal de Pernambuco , Recife, Pernambuco , Brazil.
Maria Edileuza Felinto de BritoDepartment of Immunology, Fundação Oswaldo Cruz , Recife, Pernambuco , Brazil.
Beatriz Coutinho de OliveiraDepartment of Immunology, Fundação Oswaldo Cruz , Recife, Pernambuco , Brazil.
Ailton Alvaro da SilvaDepartment of Immunology, Fundação Oswaldo Cruz , Recife, Pernambuco , Brazil.
Osvaldo Pompílio de-Melo-NetoDepartment of Microbiology, Fundação Oswaldo Cruz , Recife, Pernambuco , Brazil.
Antônio Mauro RezendeDepartment of Microbiology, Fundação Oswaldo Cruz , Recife, Pernambuco , Brazil.
Valéria Rêgo Alves PereiraDepartment of Immunology, Fundação Oswaldo Cruz , Recife, Pernambuco , Brazil.
Fundação Oswaldo Cruz · BRUniversidade Federal de Pernambuco · BRUniversidade de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The leishmaniases are neglected tropical diseases widespread throughout the globe, which are caused by protozoans from the genus Leishmania and are transmitted by infected phlebotomine flies. The development of a safe and effective vaccine against these diseases has been seen as the best alternative to control and reduce the number of cases. To support vaccine development, this work has applied an in silico approach to search for high potential peptide epitopes able to bind to different major histocompatibility complex Class I and Class II (MHC I and MHC II) molecules from different human populations. First, the predicted proteome of Leishmania braziliensis was compared and analyzed by modern linear programs to find epitopes with the capacity to trigger an immune response. This approach resulted in thousands of epitopes derived from 8,000 proteins conserved among different Leishmania species. Epitopes from proteins similar to those found in host species were excluded, and epitopes from proteins conserved between different Leishmania species and belonging to surface proteins were preferentially selected. The resulting epitopes were then clustered, to avoid redundancies, resulting in a total of 230 individual epitopes for MHC I and 2,319 for MHC II. These were used for molecular modeling and docking with MHC structures retrieved from the Protein Data Bank. Molecular docking then ranked epitopes based on their predicted binding affinity to both MHC I and II. Peptides corresponding to the top 10 ranked epitopes were synthesized and evaluated in vitro for their capacity to stimulate peripheral blood mononuclear cells (PBMC) from post-treated cutaneous leishmaniasis patients, with PBMC from healthy donors used as control. From the 10 peptides tested, 50% showed to be immunogenic and capable to stimulate the proliferation of lymphocytes from recovered individuals.

Indexed as

CD4+ CD8+ T cell epitopescutaneous leishmaniasisLeishmania braziliensisneglected tropical diseasesvaccine development

Identifiers

PMID27621732
PMCPMC5002431
OpenAlexW2508790821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.